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Abstract: 
Sexually transmitted infections (STIs) cause a socioeconomic burden, morbidity and even 
mortality in a large part of the human population all over the world today. One of the most 
common genital ulcerative diseases is caused by herpes simplex virus type 2 with over 536 
million people infected world-wide. Despite tremendous efforts, there are only vaccines 
against sexually transmitted human papillomavirus available today. The lack of success in 
vaccine development against STIs has partly been due to insufficient knowledge about how to 
induce protective immunity in the female genital tract.  
Development of new vaccines is largely based on the use of highly purified or 
recombinant antigens, with limited immunogenicity. This has generated a need for 
development of potent vaccine adjuvants. Although a few adjuvants are included in the 
licensed vaccines, they are all administered systemically and their mode of action is poorly 
defined. In this thesis we have identified two new potent mucosal adjuvants for induction of 
immunity against genital HSV-2 infection, the glycosphingolipid alpha-galactosylceramide 
(α-GalCer), which is a potent agonist of invariant natural killer T (iNKT) cells and AFCo1, a 
cochelate structure of proteoliposome derived from Neisseria Meningitides serogroup B, with 
a combined immunostimulatory and delivery system function. 
By employment of genome-wide gene expression microarray analysis combined with a 
bioinformatics approach we assessed the molecular signatures of two classes of  
immunostimulatory mucosal adjuvants, namely α-GalCer and the Toll-like receptor 9 agonist 
CpG ODN, both of which have been shown by our group to induce comparable immune 
protection against genital herpes infection in mice. Local administration of the adjuvants 
elicited expression of a number of core genes among which several were cytokines and 
chemokines as well as inflammasome associated genes. “Inflammatory response” was 
identified as the common main bio-function with Tnf as the common key regulator of gene 
expression. An adjuvant-induced enhancement in the frequency of vaginal dendritic cells and 
macrophages was also observed. 
In summary, results presented in this thesis could identify two new mucosal adjuvants 
with the ability to confer protective immunity against genital herpes, as well as the molecular 
signature of mucosal adjuvants in the mouse female genital tract. These results may contribute 
to the future development of safe and potent mucosal adjuvants to be included in novel 
vaccines against STIs. 
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